Abstract: The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.

Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.

Abstract: Use of imeglimin for the prevention and/or treatment of hepatocellular carcinoma.

Abstract: The invention provides a method of inhibiting casein kinase 1? (CK1?), comprising contacting the CK1? with a compound of formula (I) as defined herein; such as compound SR-3029. We demonstrate that CSNK1D is amplified and/or overexpressed in human breast tumors and that CK1? can be medically targeted in human breast cancer subtypes overexpressing this kinase. The invention further provides a method of treating cancer, such as a breast cancer, melanoma, glioblastoma, medulloblastoma, renal, bladder or colon cancer, or a cancer that metastasizes to the brain, lung, or bone provided that both elevated CK1? and ?-catenin dependence are involved in those metastatic diseases. The cancer can be a breast cancer of the triple negative subclass of breast cancers (TNBC), or can be an HER+ breast cancer.

Abstract: The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington's Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): or a form thereof, wherein w1, w2, w3, w4, w5, w6 and w7 are as defined herein. In particular, the present description relates to a method of use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or composition thereof to the subject.

Abstract: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.

Abstract: Injection systems comprising a powered injector and one or more hazardous agents are disclosed.

Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.

Abstract: Compositions and methods of treatment involving transpore delivery of an active ingredient are provided.

Abstract: Provided herein are conjugates of nucleoside antimetabolites and their analogs with ibandronate, pharmaceutical compositions including one or more of said conjugates, methods of synthesizing the same as well as methods of treating diseases and or conditions using the same.

Abstract: A stable, ready-to-use injectable solution including thiotepa and one or more pharmaceutically acceptable solvents, co-solvents, and/or solubilizing agents. Formulations retain at least 90% and as high as 99% of the purity of thiotepa as measured by HPLC after storage at 25° C./60% RH for a period of 7 days. Certain formulations retain at least 99% of the purity of thiotepa as measured by HPLC after storage for at least six months at 2-8° C.

Abstract: Embodiments of the invention include topical compositions comprising silica fiber powder or dust and a topical carrier, for treatment of skin tissue. The silica fiber powder or dust may be generated from silica fiber mats that may be formed via electrospinning of a sol gel produced with a silicon alkoxide reagent, such as tetraethyl ortho silicate, alcohol solvent, and an acid catalyst.

Abstract: The present invention relates to a nutritional composition comprising at least three human milk oligosaccharides, for use to increase butyrate production in the digestive tract in an infant or a young child. The production increases with the HMOs blend complexity.

Abstract: The invention relates to a composition comprising one or more human milk oligosaccharides (HMOs) for use in stimulating the production of butyrate in the gastro-intestinal tract of a non-infant human and obtaining delayed increase in the level of butyrate in the gastro-intestinal tract of the non-infant human, and methods for their use.

Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.

Abstract: Disclosed are a medicament comprising isovaleryl spiramycin I, II and/or III, and use of isovaleryl spiramycin I, II and/or III in manufacturing medicament for treating and/or preventing tumor and the medicament.

Abstract: This invention features new compositions and methods that are useful in treating a host with a Gram-negative bacterial infection. Combination therapies comprising an aminocoumarin compound and a polymyxin compound are disclosed, including certain combinations that exhibit synergistic effects. Furthermore, aminocoumarin compounds are described having altered inhibition of DNA gyrase in Gram-negative bacteria and/or the ability to target the transport proteins responsible for assembling lipopolysaccharide in the outer membrane of Gram-negative bacteria.

Abstract: The present invention relates to the use of 2-chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the autoimmune neuromuscular disorder myasthenia gravis (MG).

Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).

Abstract: The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of indoleamine-2,3-dioxygenase (IDO-1) of SEQ ID NO.1 (human) in a hybridizing active area, wherein the oligonucleotide inhibits at least 50% of the IDO-1 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.

Abstract: Described are methods and systems for delivering a pharmaceutical gas to a patient.

Abstract: Disclosed are a composition containing a transition metal, as well as a method of treatment of bacterial, or of fungal diseases using such composition. The composition functions as novel bactericides and antifungal agents. The transition metal may be in either soluble or insoluble form.

Abstract: Described are methods of producing an autologous composition useful for treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal. The method comprises preparing an anti-inflammatory/anti-catabolic component of the autologous composition comprising IL-1ra and TIMPs. An anti-inflammatory/anti-catabolic component is prepared comprising: collecting blood from the mammal; delivering the blood to a tube; incubating the blood at a temperature of from about 37° C. to about 39° C. for about 24 hours, preferably in the presence of sodium citrate; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component.

Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.

Abstract: Disclosed are therapeutic compositions, methods of preparing, and methods use for the treatment of infectious diseases and cancer. More specifically, Natural Killer Cell (NK Cell)-derived exosomes are demonstrated as potent therapeutic agents that can kill tumor cells in vivo, but do not kill normal cells. The exosomes can also be used to treat infectious disease.

Abstract: The disclosure provides an ex vivo method to prepare regulatory T cells, a population of regulatory T cells with enhanced properties and methods of using the population or complexes useful to induce Tregs in a mammal. The ex vivo methods allows for the generation and expansion of super regulatory T cells for the prevention, inhibition or treatment of autoimmune disorders.

Abstract: Disclosed herein is a pharmaceutical kit for treating cancers. The present pharmaceutical kit comprises an agent and an engineered natural killer cell. The agent is capable of increasing a tumor-associated antigen expression in cancer cells, which can then be targeted and destroyed by the engineered natural killer cell having a tumor-associated antigen-specific chimeric antigen receptor. Also disclosure herein is the uses of the present pharmaceutical kit for the treatment of cancers.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The invention provides methods and compositions for administration of allogeneic lymphocytes as an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells.

Abstract: The invention relates to methods for production of extracellular vesicle-mimetic nanovesicles from mesenchymal stem cells to treat or prevent inflammatory related conditions or diseases. Included with the invention are pharmaceutical compositions comprising extracellular vesicle-mimetic nanovesicles derived from mesenchymal stem cells for the treatment or prevention of inflammatory related conditions.

Abstract: The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Abstract: This application provides a microbiome disruption index (MDI) for determining or monitoring the taxonomic structure of an intestinal or fecal microbiota of a subject. Disclosed herein is the use of an MDI in the diagnosis, treatment or prognosis of disorders, diseases, conditions or indications caused by, associated with, or related to a gut dysbiosis. Further disclosed is the use of MDI to assess the efficacy of a microbiome-based therapy.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing autoimmune and inflammatory disorders of the central nervous system.

Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures.

Abstract: The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.

Abstract: The present invention relates to a bacterial composition and/or derivatives thereof whose biological activity has been specifically studied for the improvement of the state of health differentiated for male and female human subjects.

Abstract: The application relates to pharmaceutical compositions comprising a compound of formula I and one or more gut microbiome species, and methods of preparing and using the same.

Abstract: Provided herein are compositions comprising a carrier and one or more bioactive agents in which one or more bioactive agents are incorporated into said carrier. Sugars that are naturally present with one or more bioactive agents as mixture are preferentially excluded out of said carrier in the composition. The compositions have wide applications including, but not limited to food and beverage industries. Also provided are methods of incorporating one or more bioactive agents into a carrier, compositions comprising a carrier and one or more bioactive agents and use of such methods and compositions, and kits. The methods are useful for (a) improving color, thermal, photo, and oxidative stability of bioactive agents, e.g., natural food colorants and other bioactive ingredients, (b) reducing and eliminating the usage of artificial chemicals such as sacrificial antioxidants and metal ion chelators that are used to improve bioactive stability.

Abstract: This invention provides for a method for improving the success rate of in vitro fertilization in women hosting abnormal vaginal microbiota. The method comprises the steps of: (i) selecting a woman suspected of hosting abnormal vaginal microbiota (AVM); (ii) administering to the woman a suitable antibiotic administered in an amount and duration effective to reduce the quantity of abnormal vaginal microbiota hosted by the woman; (iii) administering to the woman via vaginal administration an amount of Lactobacillus species in an amount sufficient to colonize the vaginal mucosa; and, (iv) transferring an embryo to the woman.

Abstract: Provided are methods of treating a subject in need of treatment for a disease caused by a loss of function or activity of a protein. Also provided are methods of treating a subject in need of treatment for a disease caused by a gain of function, activity or expression, of a protein.

Abstract: The present invention relates to a new method for producing a novel fermented plant material comprising a high content of lactic acid bacterial strains and a high content of glucosinolates having nutritional and/or pharmacological effects.

Abstract: The present invention provides a method for treating dementia, in particular Alzheimer's disease, with an extract of Antrodia camphorata fruit body, or active ingredients thereof. Also provided is the use of the extract of Antrodia camphorate or active ingredients thereof for manufacturing a medicament for treating dementia, in particular Alzheimer's disease.

Abstract: The present invention discloses sporoderm-removed Ganoderma lucidum spore powder, granule and a preparation method thereof. The sporoderm-removed Ganoderma lucidum spore powder and granule is obtained from sporoderm-disrupted Ganoderma lucidum spore powder through extraction, centrifugation, sporoderm removal, concentration, drying, and pulverization; and in the sporoderm-removed Ganoderma lucidum spore powder and granule, the content of polysaccharides is 10-20 g/100 g, and the content of total triterpenes is 4-10 g/100 g. The present invention has beneficial effects of enhancing immunity and having an auxiliary protection function against radiation hazards.

Abstract: A concentrated lipid-based solution including tetrahydrocannabinol (THC) is manufactured by providing a lipid solution including an array of triglycerides, cannabinoids and water soluble contaminants in a pressure vessel. Water is added to the lipid solution to create a mixture and the pressure is increased in a first phase at a first pressure and duration and in a second phase at a second temperature and duration. The mixture is agitated to dissolve the water soluble contaminants. The mixture is cooled to cause the triglycerides and cannabinoids to solidify. The solidified triglycerides and cannabinoids, including THC, are separated to yield a purified cannabinoid solution.

Abstract: In preferred embodiments the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

Abstract: [PROBLEM] To provide a mesenchymal stem cell attracting agent, as well as an aging-factor production inhibiting agent, anti-aging agent, and dermal regeneration promoting agent including the attracting agent. [SOLVING MEANS] It was found that iris extract, olive leaf extract, and chamomile extract have a mesenchymal stem cell inducing action, which led to the invention of a mesenchymal stem cell attracting agent. Furthermore, it was discovered that mesenchymal stem cells inhibit aging factor production and activate dermal fibroblasts, whereby an aging-factor production inhibiting agent, anti-aging agent, and dermal regeneration promoting agent including the attracting agent were invented.

Abstract: An antiviral traditional Chinese medicine composition, a preparation method therefor and a pharmaceutical application thereof. The composition uses Herba Taraxaci, Radix Stemonae, Pseudobulbus Cremastrae Seu Pleiones, Radix Puerariae, Rhizoma Atractylodis Macrocephalae, and Radix Cynanchi Atrati as main active pharmaceutical ingredients, may also optionally and additionally use Cortex Lycii Radicis and Cortex Mori as active pharmaceutical ingredients, and is prepared into a pharmaceutically acceptable dosage form according to needs. The medicine composition is effective against influenza A virus, H1N1, H7N7 and H9N2 viruses, Zika virus, dengue virus I, dengue virus II, and Chikungunya virus.

Abstract: The present invention relates to a composition and health functional food for preventing and treating a respiratory inflammation disease using a mixed herbal mixture. Through various experiments, for example, determination of the cell number of BAL (bronchoalveolar lavage) (Experimental Example 1); Determination of CD11b+/Gr-1+ ratio in leukocyte within BAL fluid (Experimental Example 2); Determination of expressed RNA level of inflammatory cytokines in lung tissue (Experimental Example 3); Determination of expressed RNA level of inflammatory cytokines in BALF (Experimental Example 4); Lung histology (Experimental Example 5); Brief Clinical test (Experimental Example 7) etc, it has been verified that the inventive combined extract showed more potent inhibiting effect on respiratory inflammation disease than each herb extract.

Abstract: Provided is a kampo medicine for treating multimorbidity of Alzheimer-type dementia or mild cognitive impairment and at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney disease with one drug. A kampo medicine for treating multimorbidity with one drug, comprising a drug combination of orengedokuto and ryokeijutsukanto as an active ingredient, wherein the kampo medicine improves a cognitive function in Alzheimer-type dementia or mild cognitive impairment and relieves and treats at least one disease from overactive bladder, constipation, and chronic kidney disease complicated by Alzheimer-type dementia or mild cognitive impairment at a high rate with one drug.

Abstract: Provided are: a citrus seed extract-containing composition, a food and a drug all of which sufficiently exert a novel function of a citrus (specifically, a citrus seed extract), and a method for producing the citrus seed extract-containing composition. The citrus seed extract-containing composition includes obacunone and nomilin both derived from a citrus seed extract. Herein, the ratio of the obacunone content to the nomilin content (i.e., obacunone content/nomilin content) is at least 0.020.